A lawyer at a company regulated by the Food and Drug Administration has filed a lawsuit to prevent counsel’s personally identifiable information from being disclosed in the agency’s apparently damning inspection report scheduled for release this week.

The “reverse FOIA” case filed Tuesday in U.S. District Court for the District of Columbia raises more questions than it answers, however—including whether it is actually a clever tactic to limit disclosure of reputationally damaging information about the company.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]